miR-100-5p is upregulated in multiple myeloma and involves in the pathogenesis of multiple myeloma through targeting MTMR3

References

• Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016;43(6):676–681.
   PubMed Web of Science ®Google Scholar
• van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410–427.
   PubMed Web of Science ®Google Scholar
• Minnie SA, Hill GR. Immunotherapy of multiple myeloma. J Clin Invest. 2020;130(4):1565–1575.
   PubMed Web of Science ®Google Scholar
• Yang Y, Li Y, Gu H, et al. Emerging agents and regimens for multiple myeloma. J Hematol Oncol. 2020;13(1):150.
   PubMed Web of Science ®Google Scholar
• Hammond SM. An overview of microRNAs. Adv Drug Deliv Rev. 2015;29(87):3–14.
   Google Scholar
• Vishnoi A, Rani S. MiRNA biogenesis and regulation of diseases: An overview. Methods Mol Biol. 2017;1509:1–10.
   PubMedGoogle Scholar
• Ardizzone A, Calabrese G, Campolo M, et al. Role of miRNA-19a in cancer diagnosis and poor prognosis. Int J Mol Sci. 2021;22(9):4697.
   PubMed Web of Science ®Google Scholar
• Sabit H, Cevik E, Tombuloglu H, et al. Triple negative breast cancer in the era of miRNA. Crit Rev Oncol Hematol. 2021;157:103196.
   PubMed Web of Science ®Google Scholar
• Xu K, Zhang C, Du T, et al. Progress of exosomes in the diagnosis and treatment of lung cancer. Biomed Pharmacother. 2021;134:111111.
   PubMed Web of Science ®Google Scholar
• Chen D, Yang X, Liu M, et al. Roles of miRNA dysregulation in the pathogenesis of multiple myeloma. Cancer Gene Ther. 2021;28(12):1256–1268.
   PubMed Web of Science ®Google Scholar
• Caracciolo D, Montesano M, Altomare E, et al. The potential role of miRNAs in multiple myeloma therapy. Expert Rev Hematol. 2018;11(10):793–803.
   PubMed Web of Science ®Google Scholar
• Papadimitriou MA, Papanota AM, Adamopoulos PG, et al. miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome. Br J Cancer. 2022;126(1):79–90.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548.
   PubMed Web of Science ®Google Scholar
• Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162(1):156–159.
   PubMed Web of Science ®Google Scholar
• Mulligan G, Mitsiades C, Bryant B, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007;109(8):3177–3188.
   PubMed Web of Science ®Google Scholar
• Jakob M, Mattes LM, Kuffer S, et al. MicroRNA expression patterns in oral squamous cell carcinoma: hsa-mir-99b-3p and hsa-mir-100-5p as novel prognostic markers for oral cancer. Head Neck. 2019;41(10):3499–3515.
   PubMed Web of Science ®Google Scholar
• Chen P, Lin C, Quan J, et al. Oncogenic miR-100-5p is associated with cellular viability, migration and apoptosis in renal cell carcinoma. Mol Med Rep. 2017;16(4):5023–5030.
   PubMed Web of Science ®Google Scholar
• Liu X, Liu C, Zhang A, et al. Long non-coding RNA SDCBP2-AS1 delays the progression of ovarian cancer via microRNA-100-5p-targeted EPDR1. World J Surg Oncol. 2021;19(1):199.
   PubMed Web of Science ®Google Scholar
• Diener C, Keller A, Meese E. Emerging concepts of miRNA therapeutics: from cells to clinic. Trends Genet. 2022;38(6):613–626.
   PubMed Web of Science ®Google Scholar
• Li HP, Peng CC, Wu CC, et al. Inactivation of the tight junction gene CLDN11 by aberrant hypermethylation modulates tubulins polymerization and promotes cell migration in nasopharyngeal carcinoma. J Exp Clin Cancer Res. 2018;37(1):102.
   PubMedGoogle Scholar
• Lau HY, Tang J, Casey PJ, et al. Isoprenylcysteine carboxylmethyltransferase is critical for malignant transformation and tumor maintenance by all RAS isoforms. Oncogene. 2017;36(27):3934–3942.
   PubMed Web of Science ®Google Scholar
• Court H, Amoyel M, Hackman M, et al. Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via notch suppression. J Clin Invest. 2013;123(11):4681–4694.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhang M, Shan R, et al. MTMR3 is upregulated in patients with breast cancer and regulates proliferation, cell cycle progression and autophagy in breast cancer cells. Oncol Rep. 2019;42(5):1915–1923.
   PubMed Web of Science ®Google Scholar
• Yan Y, Yan H, Wang Q, et al. MicroRNA 10a induces glioma tumorigenesis by targeting myotubularin-related protein 3 and regulating the Wnt/beta-catenin signaling pathway. FEBS J. 2019;286(13):2577–2592.
   PubMed Web of Science ®Google Scholar
• Qiu W, Xia X, Qiu Z, et al. RasGRP3 controls cell proliferation and migration in papillary thyroid cancer by regulating the Akt-MDM2 pathway. Gene. 2017;633:35–41.
   PubMed Web of Science ®Google Scholar
• Stopka T, Zakova D, Fuchs O, et al. Chromatin remodeling gene SMARCA5 is dysregulated in primitive hematopoietic cells of acute leukemia. Leukemia. 2000;14(7):1247–1252.
   PubMed Web of Science ®Google Scholar
• Gigek CO, Lisboa LC, Leal MF, et al. SMARCA5 methylation and expression in gastric cancer. Cancer Invest. 2011;29(2):162–166.
   PubMed Web of Science ®Google Scholar
• Alrfaei BM, Clark P, Vemuganti R, et al. MicroRNA miR-100 decreases glioblastoma growth by targeting SMARCA5 and ErbB3 in tumor-initiating cells. Technol Cancer Res Treat. 2020;19:1533033820960748.
   Web of Science ®Google Scholar
• He Y, Sun MM, Zhang GG, et al. Targeting PI3K/Akt signal transduction for cancer therapy. Signal Transduct Target Ther. 2021;6(1):425.
   PubMed Web of Science ®Google Scholar
• Hatch AJ, York JD. Snapshot: inositol phosphates. Cell. 2010;143(6):1030–1030. e1.
   PubMed Web of Science ®Google Scholar
• Dovey CM, Diep J, Clarke BP, et al. MLKL requires the inositol phosphate code to execute necroptosis. Mol Cell. 2018;70(5):936–948. e7.
   PubMed Web of Science ®Google Scholar
• Manna A, Zhao H, Wada J, et al. Cooperative assembly of a four-molecule signaling complex formed upon T cell antigen receptor activation. Proc Natl Acad Sci U S A. 2018;115(51):E11914–E11923.
   PubMed Web of Science ®Google Scholar
• Watson PJ, Millard CJ, Riley AM, et al. Insights into the activation mechanism of class I HDAC complexes by inositol phosphates. Nat Commun. 2016;7:11262.
   PubMed Web of Science ®Google Scholar
• Wei Y, Jasbi P, Shi X, et al. Early breast cancer detection using untargeted and targeted metabolomics. J Proteome Res. 2021;20(6):3124–3133.
   PubMed Web of Science ®Google Scholar
• Zhu G, Wang Y, Wang W, et al. Untargeted GC-MS-based metabolomics for early detection of colorectal cancer. Front Oncol. 2021;11:729512.
   PubMed Web of Science ®Google Scholar
• Han K, Xu X, Chen G, et al. Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization. J Hematol Oncol. 2014;7:9.
   PubMed Web of Science ®Google Scholar
• Younes A, Berdeja JG, Patel MR, et al. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. Lancet Oncol. 2016;17(5):622–631.
   PubMed Web of Science ®Google Scholar
• Wang B, Mao JH, Wang BY, et al. Exosomal miR-1910-3p promotes proliferation, metastasis, and autophagy of breast cancer cells by targeting MTMR3 and activating the NF-kappaB signaling pathway. Cancer Lett. 2020;489:87–99.
   PubMed Web of Science ®Google Scholar